Latest Headlines
-
Bioxytran’s Oral Antiviral Drug To Enter Dose Optimization Clinical Trial For COVID-19
2/21/2024
BIOXYTRAN, INC. (OTCQB: BIXT), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, announced that the first patients have been treated with ProLectin-M in its dose optimization trial.
-
Vaccinex Announces Multiple New Agreements For Access To ActivMAb® Antigen Virus Technology
2/21/2024
Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease and cancer through the inhibition of SEMA4D, announces that it has entered into eight new antibody discovery agreements integrating use of its proprietary ActivMAb platform to select antibodies against difficult-to-drug transmembrane protein targets.
-
‘Protein Sandwich’ Could Transform Cancer Drug Discovery
2/21/2024
A research team at the University’s Centre for Targeted Protein Degradation (CeTPD) led by Professor Alessio Ciulli, in collaboration with the research group of Dr Georg Winter at the Research Center for Molecular Medicine (CEMM) of the Austrian Academy of Sciences in Vienna, have defined a new class of so-called “intramolecular bivalent glue,” which bind proteins – crucial to the cells that allow our bodies to function correctly – that would otherwise stay apart.
-
For The First Time, Quantum-Enhanced Generative AI Generates Viable Cancer Drug Candidates
2/20/2024
Zapata Computing, Inc. (“Zapata AI” or the “Company”), the Industrial Generative AI company, today announced that its scientists, in collaboration with Insilico Medicine, the University of Toronto, and St. Jude Children’s Research Hospital have demonstrated the first instance of a generative model running on quantum hardware outperforming state-of-the-art classical models in generating viable cancer drug candidates.
-
Hox Therapeutics And Vernalis Announce A Drug Discovery Collaboration In Oncology
2/20/2024
Hox Therapeutics Ltd ("Hox") a private biotechnology company developing highly targeted cancer therapies and Vernalis (R&D) Ltd ("Vernalis"), a fully owned subsidiary of HitGen Inc., are pleased to announce a collaboration to identify inhibitors against an undisclosed oncology target.
-
Salk Scientists Discover New Target For Reversible, Non-Hormonal Male Birth Control
2/20/2024
Surveys show most men in the United States are interested in using male contraceptives, yet their options remain limited to unreliable condoms or invasive vasectomies.
-
PepGen Receives U.S. FDA Fast Track Designation For PGN-EDODM1 For The Treatment Of Myotonic Dystrophy Type 1
2/20/2024
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PGN-EDODM1, an investigational candidate for the treatment of myotonic dystrophy type 1 (DM1).
-
WuXi Advanced Therapies Receives FDA Approval To Manufacture Iovance’s AMTAGVI (Lifileucel) For Advanced Melanoma
2/20/2024
WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced that the U.S. Food and Drug Administration (FDA) has approved its Philadelphia site to begin the analytical testing and manufacturing of AMTAGVI for Iovance, which received FDA accelerated approval of its Biologics License Application (BLA) on February 16, 2024.
-
InveniAI Announces Collaboration With Ono Pharmaceutical For Target Discovery
2/19/2024
InveniAI® LLC, a global leader in the application of artificial intelligence (AI) and machine learning (ML) tools to revolutionize drug discovery and development, announces a strategic collaboration with Ono Pharmaceutical Co., Ltd. (Ono), a renowned pharmaceutical company committed to advancing innovative solutions for unmet medical needs.
-
Atara Biotherapeutics Announces Submission Of Investigational New Drug Application For ATA3219 For Treatment Of Lupus Nephritis
2/14/2024
Atara Biotherapeutics, Inc. a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced its recent submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the use of ATA3219 as a monotherapy for the treatment of systemic lupus erythematosus (SLE) with kidney involvement (lupus nephritis [LN]).